Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: Influence of application site - A clinical research center study

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 5, 1996, Pages 1832-1840

  Meikle, A Wayne ^a   Arver, Stefan ^c   Dobs, Adrian S ^d   Sanders, Steven W ^e   Rajaram, Lakshminaryan ^e   Mazer, Norman A ^b,e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e TheraTech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ESTRADIOL; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOGONADOTROPIC HYPOGONADISM; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TRANSDERMAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DIHYDROTESTOSTERONE; ESTRADIOL; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOGONADISM; KINETICS; LUTEINIZING HORMONE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; TESTOSTERONE;

EID: 0029930211     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.5.1832     Document Type: Article

References (50)

1. Behre HM, Oberpenning F, Nieschlag E. 1990 Comparative pharmacokinetics of androgen preparations: application of computer analysis and simulation. In: Nieschlag E, Behre HM, eds. Testosterone-action, deficiency, substitution. Berlin: Springer-Verlag; 115-135.
2. Bhasin S. 1992 Clinical review 34: androgen treatment of hypogonadal men. J Clin Endocrinol Metab. 74:1221-1225.
3. Snyder PJ, Lawrence DA. 1980 Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab. 51:1335-1339.
4. Sokol RZ, Palacios A, Campfield LA, Saul CC, Swerdloff RS. 1982 Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. Fertil Steril. 37:425-430.
5. Behre MH, Nieschlag E. 1992 Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab. 75:1204-1210.
6. Handelsman DJ, Conway J, Boylan LN. 1990 Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab. 71: 216-222.
7. Korenman SG, Viosca S, Garza D, et al. 1987 Androgen therapy of hypogonadal men with transscrotal testosterone systems. Am J Med. 83:471-478.
8. Findlay JC, Place VA, Snyder PJ. 1987 Transdermal delivery of testosterone. J Clin Endocrinol Metab. 64:266-268.
9. Bals-Pratsch M, Yoon Y-D, Knuth UA, Nieschlag E. 1986 Transdermal testosterone Substitution therapy for male hypogonadism. Lancet. 2:943-946.
10. Ahmed SR, Boucher AE, Manni A, et al. 1988 Transdermal testosterone therapy in the treatment of male hypogonadism. J Clin Endocrinol Metab. 66:546-551.
11. Findlay JC, Place V, Snyder PJ. 1989 Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J Clin Endocrinol Metab. 69:369-373.
12. Cunningham GR, Cordero E, Thornby JI. 1989 Testosterone replacement with transdermal therapeutic systems. JAMA. 261:2525-2530.
13. Johnsen SG, Bennett EP, Jensen VG. 1974 Therapeutic effectiveness of oral testosterone. Lancet. 2:1473-1475.
14. Cantrill J, Dewis P, Large DM, Newman M, Anderson DC. 1984 Which testosterone replacement therapy? Clin Endocrinol (Oxf). 21:97-107.
15. Franchi F, Luisi M, Kicovic PM. 1978 Long term study of oral testosterone undecanoate in hypogonadal males. Int J Androl. 1:270-278.
16. Stuenkel CA, Dudley RE, Yen SCC. 1991 Sublingual administration of testosterone-hydroxylpropyl-β-cyclodextrin inclusion complex simulates episodic androgen release. J Clin Endocrinol Metab. 72:1054-1059.
17. Burris AS, Ewing LL, Sherins RJ. 1988 Initial trial of slow-release testosterone microspheres in hypogonadal men. Fertil Steril. 50:493-497.
18. Bhasin S, Swerdloff RS, Steiner B, et al. 1992 A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J Clin Endocrinol Metab. 74:75-83.
19. Meikle AW, Mazer NA, Moellmer JF, et al. 1992 Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab. 74:623-628.
20. Mazer NA, Sanders SW, Ebert CD, Meikle AW. 1993 Mimicking the circadian pattern of testosterone and metabolite levels with an enhanced transdermal delivery system. In: Gurney R, Junginger HE, Peppas N, eds. Pulsatile drug delivery: current applications and future trends. Stuttgart: Wissenshaftliche Verlagsgesellschaft mbH; 73-97.
21. Arver S, Dobs AS, Meikle AW, et al. Hormone levels, endocrine responses and sexual function in hypogonadal men treated for one year with a non-scrotal testosterone transdermal delivery system (T-TDS). Proc of the 76th Annual Meet of The Endocrine Soc. 1994;527.
22. Furuyama S, Mayes D, Nugent CA. 1970 Radioimmunoassay for plasma testosterone. Steroids. 16:415-428.
23. Wu C, Lundy L. 1971 Radioimmunoassay for plasma estrogens. Steroids. 18:91-111.
24. Nankin HR, Pinto R, Fan D-F, Troen P. 1975 Daytime titers of testosterone, LH, estrone, estradiol and testosterone-binding protein: acute effects of LH and LH-releasing hormone in men. J Clin Endocrinol Metab. 41:271-281.
25. Mazer NA, Heiber WE, Moellmer JF, et al. 1992 Enhanced transdermal delivery of testosterone: a new physiological approach for androgen replacement in hypogonadal men. J Contr Rel. 19:347-362.
26. Gibaldi M, Perrier D. 1982 Pharmacokinetics, 2nd ed. New York: Marcel Dekker.
27. Rowland M, Tozer TN. 1989 Clinical pharmacokinetics: concepts and applications, 2nd ed. Philadelphia: Lea and Febiger; 347-375.
28. Baird DT, Horton R, Longcope C, Tait JF. 1969 Steroid dynamics under steady-state conditions. Recent Prog Horm Res. 25:611-664.
29. Wagner JG, Nelson E. 1963 Percent absorbed time plots derived from blood level and/or urinary excretion data. J Pharm Sci. 52:610-611.
30. Vermuelen A, Ando S. 1979 Metabolic clearance rate and interconversion of androgens and the influence of the free androgen fraction. J Clin Endocrinol Metab. 48:320-326.
31. Marzulli FN, Maibach HI. 1973 Antimicrobials: experimental contact sensitization in man. J Soc Cosmet Chem. 24:399-421.
32. ™ TDS. In: Crommelin DJA, Midha KK, eds. Topics in pharmaceutical sciences 1991. Stuttgart: Medpharm; 149-170.
33. 14-testosterone in human subjects. I. Distribution in bile, blood, feces and urine. J Clin Invest. 35:1331-1339.
34. Southren AL, Tochimoto S, Carmody NC, Isurugi K. 1965 Plasma production rates of testosterone in normal adult men and women and in patients with the syndrome of feminizing testes. J Clin Endocrinol Metab. 25:1441-1450.
35. 3H in man. Distribution of the major 17-ketosteroid metabolites in plasma: relation to thyroid states. J Clin Endocrinol Metab. 38:424-435.
36. 3H-5α-dihydrotestosterone metabolism in normal and women and men with prostatic carcinoma: effects of estrogen administration in men. J Clin Endocrinol Metab. 34:467-472.
37. 3H-estrone. J Clin Endocrinol Metab. 38:602-607.
38. 14 Cortisol in man. J Invest Dermatol. 48:181-183.
39. Schenkel L, Barlier D, Riera M, Barner A. 1986 Transdermal absorption of estradiol from different body sites is comparable. J Contr Rel. 4:195-201.
40. Mahoudeau JA, Bardin CW, Lipsett MB. 1971 The metabolic clearance rate and origin of plasma dihydrotestosterone in man and its conversion to the 5 α-androstanediols. J Clin Invest. 50:1338-1344.
41. Ishimaru T, Pages L, Horton R. 1977 Altered metabolism of androgens in elderly men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 45: 695-701.
42. Ishimaru T, Edmiston WA, Pages L, Horton R. 1978 Splanchnic extraction and conversion of testosterone and dihydrotestosterone in man. J Clin Endocrinol Metab. 46:528-533.
43. Longcope C, Kato T, Horton R. 1969 Conversion of blood androgens to estrogens in normal adult men and women. J Clin Invest. 48:2191-2201.
44. Wilson JD, Walker JD. 1969 The conversion of testosterone to 5a-androstane-17§-ol-3-one (dihydrotestosterone) by skin slices of man. J Clin Invest. 48:371-379.
45. ™: a permeation enhanced non-scrotal testosterone transdermal system for the treatment of male hypogonadism. In: Bhasin S, et al, eds. Pharmacology, Biology, and Clinical Applications of Androgens 1996. New York: Wiley-Liss; 449-457.
46. Southern AL, Gordon GC, Tochimoto S. 1968 Further study of factors affecting the metabolic clearance rate of testosterone in man. J Clin Endocrinol Metab. 28:1105-1112.
47. Vermeulen A, Rubens R, Verdonck L. 1972 Testosterone secretion and metabolism in male senescence. J Clin Endocrinol Metab. 34:730-735.
48. Meikle AW, Stringham JD, Bishop DT, West DE. 1988 Quantitating genetic and nongenetic factors influencing androgen production and clearance rates in men. J Clin Endocrinol Metab. 67:104-109.
49. Morimoto I, Edmiston A, Hawks D, Horton R. 1981 Studies on the origin of androstanediol and androstanediol glucuronide in young and elderly men. J Clin Endocrinol Metab. 52:772-778.
50. Bradley SE, Inglefinger FJ, Bradley GP, Curry JJ. 1945 The estimation of hepatic blood flow in man. J Clin Invest. 24:890-897.